Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 75, No 2 (2024)
Original paper
Submitted: 2024-01-25
Accepted: 2024-02-03
Published online: 2024-03-19
View PDF Download PDF file
Get Citation

Circulating levels of irisin and Meteorin-like protein in PCOS and its correlation with metabolic parameters

Katarzyna Paczkowska1, Joachim Sobczuk2, Katarzyna Zawadzka1, Diana Jędrzejuk1, Agnieszka Zembska1, Jacek Konieczny3, Dorota Kaszubkiewicz-Wardęga4, Marek Bolanowski1, Jacek Daroszewski1
DOI: 10.5603/ep.99111
·
Pubmed: 38646985
·
Endokrynol Pol 2024;75(2):199-206.
Affiliations
  1. Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland
  2. Department of Endocrinology, Diabetes and Isotope Therapy, University Clinical Hospital, Wroclaw, Poland
  3. CodeAI, Poznan, Poland
  4. 2nd Department of Gynecology and Obstetrics, University Clinical Hospital, Wroclaw, Poland

open access

Vol 75, No 2 (2024)
Original Paper
Submitted: 2024-01-25
Accepted: 2024-02-03
Published online: 2024-03-19

Abstract

Introduction: Research on obesity, which results from excessive food consumption and sedentary lifestyle, has focused on increasing energy expenditure. Recently, muscle tissue is being investigated as an endocrine active organ, secreting molecules called myokines. Multiple studies have been performed to assess myokine levels in various disorders, including polycystic ovary syndrome (PCOS) and metabolic syndrome. Irisin and Meteorin-like protein (Metrnl) are particles which, among others, are suggested to play an important role in adipose tissue browning and improving insulin sensitivity.

Material and methods: The study population consisted of 31 women with PCOS and 18 healthy individuals. PCOS was diagnosed based on revised 2003 Rotterdam criteria. Multiple anthropometrical, hormonal, and biochemical parameters were assessed, including oral glucose tolerance test and body composition with dual energy X-ray absorptiometry. Serum levels of irisin and Metrnl were measured
by enzyme-linked immunosorbent assay (ELISA).

Results: There were no differences between the PCOS and control groups according to age, body mass index (BMI), waist-to-hip ratio (WHR), fasting glucose, homeostasis model assessment of insulin resistance (HOMA-IR), or body mass composition. Assessment of Metrnl and irisin concentrations revealed no significant differences between PCOS and healthy women. The irisin level was negatively
correlated with BMI, body fat mass, fasting glucose, and insulin concentrations. No relationship between Metrnl level and metabolic parameters was found.

Conclusions: Although irisin seems to be a promising biomarker, inconsistent research limits its value in clinical use in the assessment or treatment of obesity. Metrnl level was not affected in the study population, but it might be connected to the severity of metabolic disturbances.

Abstract

Introduction: Research on obesity, which results from excessive food consumption and sedentary lifestyle, has focused on increasing energy expenditure. Recently, muscle tissue is being investigated as an endocrine active organ, secreting molecules called myokines. Multiple studies have been performed to assess myokine levels in various disorders, including polycystic ovary syndrome (PCOS) and metabolic syndrome. Irisin and Meteorin-like protein (Metrnl) are particles which, among others, are suggested to play an important role in adipose tissue browning and improving insulin sensitivity.

Material and methods: The study population consisted of 31 women with PCOS and 18 healthy individuals. PCOS was diagnosed based on revised 2003 Rotterdam criteria. Multiple anthropometrical, hormonal, and biochemical parameters were assessed, including oral glucose tolerance test and body composition with dual energy X-ray absorptiometry. Serum levels of irisin and Metrnl were measured
by enzyme-linked immunosorbent assay (ELISA).

Results: There were no differences between the PCOS and control groups according to age, body mass index (BMI), waist-to-hip ratio (WHR), fasting glucose, homeostasis model assessment of insulin resistance (HOMA-IR), or body mass composition. Assessment of Metrnl and irisin concentrations revealed no significant differences between PCOS and healthy women. The irisin level was negatively
correlated with BMI, body fat mass, fasting glucose, and insulin concentrations. No relationship between Metrnl level and metabolic parameters was found.

Conclusions: Although irisin seems to be a promising biomarker, inconsistent research limits its value in clinical use in the assessment or treatment of obesity. Metrnl level was not affected in the study population, but it might be connected to the severity of metabolic disturbances.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

irisin; Meteorin-like protein; Metrnl; myokines; metabolic disturbances; obesity; PCOS

About this article
Title

Circulating levels of irisin and Meteorin-like protein in PCOS and its correlation with metabolic parameters

Journal

Endokrynologia Polska

Issue

Vol 75, No 2 (2024)

Article type

Original paper

Pages

199-206

Published online

2024-03-19

Page views

160

Article views/downloads

44

DOI

10.5603/ep.99111

Pubmed

38646985

Bibliographic record

Endokrynol Pol 2024;75(2):199-206.

Keywords

irisin
Meteorin-like protein
Metrnl
myokines
metabolic disturbances
obesity
PCOS

Authors

Katarzyna Paczkowska
Joachim Sobczuk
Katarzyna Zawadzka
Diana Jędrzejuk
Agnieszka Zembska
Jacek Konieczny
Dorota Kaszubkiewicz-Wardęga
Marek Bolanowski
Jacek Daroszewski

References (62)
  1. World Health Organization. Media Centre. Obesity and overweight: fact sheet. http://www.who.int/mediacentre/factsheets/fs311/en/ (10 April 2018).
  2. Afshin A, Forouzanfar MH, Reitsma MB, et al. GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017; 377(1): 13–27.
    CrossRefPubMed
  3. Kinlen D, Cody D, O'Shea D. Complications of obesity. QJM. 2018; 111(7): 437–443.
    CrossRefPubMed
  4. Mendonça FM, Soares R, Carvalho D, et al. The impact of obesity on bone health: an overview. Endokrynol Pol. 2022; 73(6): 954–958.
    CrossRefPubMed
  5. Kuryłowicz AE. Adipose tissue as a cause of endocrine dysfunction. Endokrynol Pol. 2023; 74(5): 468–479.
    CrossRefPubMed
  6. Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, et al. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006; 166(19): 2081–2086.
    CrossRefPubMed
  7. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2: 16057.
    CrossRefPubMed
  8. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023; 108(10): 2447–2469.
    CrossRefPubMed
  9. Pedersen BK, Akerström TCA, Nielsen AR, et al. Role of myokines in exercise and metabolism. J Appl Physiol (1985). 2007; 103(3): 1093–1098.
    CrossRefPubMed
  10. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481(7382): 463–468.
    CrossRefPubMed
  11. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61(12): 1725–1738.
    CrossRefPubMed
  12. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017; 13(6): 324–337.
    CrossRefPubMed
  13. Lee HJ, Lee JOk, Kim N, et al. Irisin, a Novel Myokine, Regulates Glucose Uptake in Skeletal Muscle Cells via AMPK. Mol Endocrinol. 2015; 29(6): 873–881.
    CrossRefPubMed
  14. Huh JY, Mougios V, Kabasakalis A, et al. Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab. 2014; 99(11): E2154–E2161.
    CrossRefPubMed
  15. Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013; 18(5): 649–659.
    CrossRefPubMed
  16. Jodeiri Farshbaf M, Alviña K. Multiple Roles in Neuroprotection for the Exercise Derived Myokine Irisin. Front Aging Neurosci. 2021; 13: 649929.
    CrossRefPubMed
  17. Villarroya F. Irisin, turning up the heat. Cell Metab. 2012; 15(3): 277–278.
    CrossRefPubMed
  18. Anastasilakis AD, Polyzos SA, Saridakis ZG, et al. Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition. J Clin Endocrinol Metab. 2014; 99(9): 3247–3255.
    CrossRefPubMed
  19. Pinkowska A, Podhorska-Okołów M, Dzięgiel P, et al. The Role of Irisin in Cancer Disease. Cells. 2021; 10(6).
    CrossRefPubMed
  20. Cebulski K, Nowińska K, Jablońska K, et al. Expression of Irisin/FNDC5 in Breast Cancer. Int J Mol Sci. 2022; 23(7).
    CrossRefPubMed
  21. Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013; 98(12): 4899–4907.
    CrossRefPubMed
  22. Li Z, Gao Z, Sun T, et al. Meteorin-like/Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: A comprehensive review of preclinical and clinical studies. Front Immunol. 2023; 14: 1098570.
    CrossRefPubMed
  23. Nishino J, Yamashita K, Hashiguchi H, et al. Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension. EMBO J. 2004; 23(9): 1998–2008.
    CrossRefPubMed
  24. Alizadeh H. Meteorin-like protein (Metrnl): A metabolic syndrome biomarker and an exercise mediator. Cytokine. 2022; 157: 155952.
    CrossRefPubMed
  25. Zheng SL, Li ZY, Song J, et al. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016; 37(5): 571–579.
    CrossRefPubMed
  26. Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014; 157(6): 1279–1291.
    CrossRefPubMed
  27. Jung TW, Lee SH, Kim HC, et al. METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice. Exp Mol Med. 2018; 50(9): 1–11.
    CrossRefPubMed
  28. Timurkaan M, Timurkaan ES. Two Important Players for Type 2 Diabetes Mellitus: Metrnl and Asprosin. Clin Lab. 2022; 68(9).
    CrossRefPubMed
  29. Rupérez C, Ferrer-Curriu G, Cervera-Barea A, et al. Meteorin-like/Meteorin-β protects heart against cardiac dysfunction. J Exp Med. 2021; 218(5).
    CrossRefPubMed
  30. Miao ZW, Hu WJ, Li ZY, et al. Involvement of the secreted protein Metrnl in human diseases. Acta Pharmacol Sin. 2020; 41(12): 1525–1530.
    CrossRefPubMed
  31. Alizadeh H. Myokine-mediated exercise effects: the role of myokine meteorin-like hormone (Metrnl). Growth Factors. 2021; 39(1-6): 71–78.
    CrossRefPubMed
  32. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
    CrossRefPubMed
  33. Obesity: preventing and managing the global epidemic: report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894(I–XII): 1–253.
  34. http://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/.
  35. Stovall DW, Bailey AP, Pastore LM. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt). 2011; 20(1): 37–43.
    CrossRefPubMed
  36. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
    CrossRefPubMed
  37. Jahromi BN, Borzou N, Parsanezhad ME, et al. Associations of insulin resistance, sex hormone-binding globulin, triglyceride, and hormonal profiles in polycystic ovary syndrome: A cross-sectional study. Int J Reprod Biomed. 2021; 19(7): 653–662.
    CrossRefPubMed
  38. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Irisin in metabolic diseases. Endocrine. 2018; 59(2): 260–274.
    CrossRefPubMed
  39. Li M, Yang M, Zhou X, et al. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015; 100(4): 1485–1493.
    CrossRefPubMed
  40. Bonfante IL, Chacon-Mikahil MP, Brunelli DT, et al. Obese with higher FNDC5/Irisin levels have a better metabolic profile, lower lipopolysaccharide levels and type 2 diabetes risk. Arch Endocrinol Metab. 2017; 61(6): 524–533.
    CrossRefPubMed
  41. Shi X, Lin M, Liu C, et al. Elevated circulating irisin is associated with lower risk of insulin resistance: association and path analyses of obese Chinese adults. BMC Endocr Disord. 2016; 16(1): 44.
    CrossRefPubMed
  42. Adamska A, Karczewska-Kupczewska M, Lebkowska A, et al. Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome. Endocr J. 2016; 63(12): 1107–1112.
    CrossRefPubMed
  43. Bostancı MS, Akdemir N, Cinemre B, et al. Serum irisin levels in patients with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2015; 19(23): 4462–4468.
    PubMed
  44. Abali R, Temel Yuksel I, Yuksel MA, et al. Implications of circulating irisin and Fabp4 levels in patients with polycystic ovary syndrome. J Obstet Gynaecol. 2016; 36(7): 897–901.
    CrossRefPubMed
  45. Chang CL, Huang SYu, Soong YK, et al. Circulating irisin and glucose-dependent insulinotropic peptide are associated with the development of polycystic ovary syndrome. J Clin Endocrinol Metab. 2014; 99(12): E2539–E2548.
    CrossRefPubMed
  46. Pukajło K, Łaczmański Ł, Kolackov K, et al. Irisin plasma concentration in PCOS and healthy subjects is related to body fat content and android fat distribution. Gynecol Endocrinol. 2015; 31(11): 907–911.
    CrossRefPubMed
  47. Cai X, Qiu S, Li L, et al. Circulating irisin in patients with polycystic ovary syndrome: a meta-analysis. Reprod Biomed Online. 2018; 36(2): 172–180.
    CrossRefPubMed
  48. Li H, Xu X, Wang X, et al. Free androgen index and Irisin in polycystic ovary syndrome. J Endocrinol Invest. 2016; 39(5): 549–556.
    CrossRefPubMed
  49. Bacopoulou F, Athanasopoulos N, Efthymiou V, et al. Serum irisin concentrations in lean adolescents with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018; 88(4): 585–591.
    CrossRefPubMed
  50. Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998; 83(6): 2001–2005.
    CrossRefPubMed
  51. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991; 72(1): 83–89.
    CrossRefPubMed
  52. Rincon J, Holmäng A, Wahlström EO, et al. Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. Diabetes. 1996; 45(5): 615–621.
    CrossRefPubMed
  53. Fouani FZ, Fadaei R, Moradi N, et al. Circulating levels of Meteorin-like protein in polycystic ovary syndrome: A case-control study. PLoS One. 2020; 15(4): e0231943.
    CrossRefPubMed
  54. Deniz R, Yavuzkir S, Ugur K, et al. Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. J Obstet Gynaecol. 2021; 41(2): 279–284.
    CrossRefPubMed
  55. Löffler D, Landgraf K, Rockstroh D, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes (Lond). 2017; 41(1): 112–119.
    CrossRefPubMed
  56. Wang K, Li F, Wang C, et al. Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance. Med Sci Monit. 2019; 25: 2337–2343.
    CrossRefPubMed
  57. AlKhairi I, Cherian P, Abu-Farha M, et al. Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin. Cells. 2019; 8(10).
    CrossRefPubMed
  58. Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, et al. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. Int J Obes (Lond). 2018; 42(4): 919–922.
    CrossRefPubMed
  59. Ding X, Chang X, Wang J, et al. Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile. Front Endocrinol (Lausanne). 2022; 13: 938341.
    CrossRefPubMed
  60. Chung HS, Hwang SY, Choi JuH, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pract. 2018; 136: 100–107.
    CrossRefPubMed
  61. Dadmanesh M, Aghajani H, Fadaei R, et al. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One. 2018; 13(9): e0204180.
    CrossRefPubMed
  62. Du Y, Ye X, Lu A, et al. Inverse relationship between serum Metrnl levels and visceral fat obesity (VFO) in patients with type 2 diabetes. Diabetes Res Clin Pract. 2020; 161: 108068.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl